Strategies for Building Early-Stage Pipelines Through External Sources

Strategies for Building Early-Stage Pipelines Through External Sources published by Decision Resources, Inc. in July, 2009. This report consists of 29 Pages and the price starts from US $ 3450.

Introduction

Abstract

Introduction

Under tremendous pressure to refuel dwindling development pipelines and improve R&D productivity, pharmaceutical companies are seeking external sources of products and innovation. Biotech companies offer valuable technologies, targets, and compounds. Pharma companies best able to access these assets and adopt new business and R&D models to develop them will be most competitive.

• Pharmaceutical companies are seeking new ways to build early-stage pipelines. What strategies are available to companies to access early-stage products and technologies? What are the benefits and risks of these strategies? What factors drive decision making for choosing strategies?
• External sources offer a variety of valuable early-stage assets. What types of assets are available for building early-stage pipelines? Which companies are the most useful sources of these assets? Which pharmaceutical companies are targeting particular types of companies and assets?
• Recent high-value deals exemplify different strategies for accessing external sources for building up early-stage pipelines. What corporate strategies do these deals serve? What are the structure and value of these deals? How do these deals illuminate current industry trends and opportunities in building early-stage pipelines?

Scope

• The need for innovation in building early-stage pipelines: R&D spending versus productivity, patent expirations, acquisition targets.
• Strategies for accessing innovation: Mergers and acquisitions (M&As), corporate partnerships, academic collaborations.
• Strategies for building pipelines through partnering: Development compounds, novel targets, technology platforms.
• Select deal highlights in building early-stage pipelines: Novel product classes, diseasemodifying drugs, early-stage compounds, programs around novel targets, broad platform technologies, proprietary platform technologies, technologies for drug repositioning, product class diversifi cation.
• Technologies of interest: RNA interference (RNAi), microRNA, large molecules, biologics, glycosylation, antisense, oligonucleotides, DNA vaccine immunotherapy, structurebased drug design, deuterium - based dugs.
• Industry outlook: Restructuring internal R&D, need for corporate partnerships, reallocation of R&D resources, shifts in industry structure, novel ways to generate external innovation, corporate venture capital.

Mentioned in This Report

• Ablynx
• Acceleron Pharma
• Adnexus
• Affiris
• Alnylam Pharmaceuticals
• Amgen
• Apiptope
• Archemix
• Ardea Biosciences
• Astellas Pharma
• Astex Technology
• AstraZeneca
• Bayer Healthcare
• Bayer Schering Pharma
• Bayhill Therapeutics
• Biogen Idec
• Bioinvent
• BiolineRX
• Biotica Technology
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Catalyst Biosciences
• Celgene
• Celldex
• Chroma Therapeutics
• CoMentis
• Concert Pharmaceuticals
• Cougar Biotechnology
• Cytokinetics
• Cytos
• Dyax
• Dynavax
• Eli Lilly
• Ensemble Discovery
• Epistem
• Exelixis
• Forma Therapeutics
• Galapagos
• Genentech
• Genzyme
• GlaxoSmithKline
• GlycoFi
• Idenix
• Ikaria
• Janssen Pharmaceutica
• Johnson & Johnson
• Kyowa Hakko Kogyo
• Lpath Therapeutics
• Maxygen
• MedImmune
• Merck
• Merck KGaA
• Merck Serono
• Micromet
• Millennium Pharmaceuticals
• Mpex Pharmaceuticals
• Neurosearch
• Novartis
• Oxford Biotherapeutics
• Peptimmune
• Pfizer
• Plexxikon
• Portola Pharmaceuticals
• Roche
• Sanofi-Aventis
• Santaris
• Sirtris Pharmaeuticals
• Symphogen
• Tacere
• Takeda Pharmaceuticals
• Thrombogenics
• Vitae Pharmaceuticals
• Wyeth
• Zydus Cadila
• Zymogenetics

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Strategies for Accessing Innovation
  • Mergers and Acquisitions
  • Corporate Partnerships
  • Academic Collaborations
• Strategies for Building Early-Stage Pipelines Through Partnering
  • Novel Targets
  • Technology Platforms
• Select Deal Highlights
  • Genentech/Bayhill Therapeutics
  • Boehringer Ingelheim/Vitae Pharmaceuticals
  • GlaxoSmithKline/Concert Pharmaceuticals
  • Sanofi -Aventis/Exelixis
  • Wyeth/Santaris Pharma
  • Alnylam/Takeda
  • Merck/GlycoFi
• Industry Outlook

Tables

• 1. Patent Expirations for Select Blockbuster Drugs
• 2. Select Recent Corporate Partnerships: Discovery and Preclinical
• 3. Select Corporate Partnerships: Early-Stage Clinical Development
• 4. Select Corporate Venture Capital Funds

Figures

• 1. R&D Spending vs. FDA New Molecular Entity Approvals, 1997-2008
• 2. Percentage of Inlicensed Products in Pipelines of Top Pharmaceutical Companies
• 3. Factors Infl uencing Early-Stage Pharma-Biotech Dealmaking

Related Reports